KUROS BIOSCI.AG.
YTSN.XETRA | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Kuros Biosciences AG is a Switzerland-based company focused on the development, manufacturing, and commercialization of innovative products for tissue repair and regeneration. The company's primary focus is on bone graft substitutes and sealants. Their products are used in spinal fusion, orthopedics...Show More
Better Health for All
20
Kuros Biosciences' primary product, MagnetOs, generated CHF 74.8 million in direct sales in 2024, accounting for 98.94% of its CHF 75.6 million total revenue.
1
A peer-reviewed Level 1 clinical study confirmed MagnetOs as a standalone alternative to autograft.
2
,
3
,
4
demonstrating a 78% fusion rate compared to 45% with autograft, and an 80% fusion rate in smokers compared to 32% with autograft.
5
The company's R&D costs in 2024 were CHF 7.0 million, representing 9.26% of its total revenue.
6
Fair Money & Economic Opportunity
0
Kuros Biosciences AG is a medical technology company focused on the development, manufacturing, and commercialization of products for tissue repair and regeneration, such as bone graft substitutes and sealants. The provided articles detail the company's financial performance
1
, medical device sales
2
, and ownership structure
3
. There is no evidence within the articles to suggest that Kuros Biosciences AG engages in activities related to lending, insuring, moving, or storing money, nor does it offer financial products or services to consumers. Therefore, all KPIs under the 'Fair Money & Economic Opportunity' ethical value are not applicable to the company's core business model.
Fair Pay & Worker Respect
0
No specific, quantitative data is available in the provided articles to assess Kuros Biosciences AG against the KPIs for Fair Pay & Worker Respect. Information regarding living wage coverage, CEO to median employee pay ratio, collective bargaining share, safety incident rates, pay equity ratio, worker engagement scores, employee turnover rate, labor violation incidents, insecure contract share, or health insurance coverage is not disclosed.
1
Fair Trade & Ethical Sourcing
0
No specific, concrete data points or relevant evidence were found in the provided article to assess Kuros Biosciences AG against any of the Fair Trade & Ethical Sourcing KPIs.
1
Honest & Fair Business
10
The company reported one restatement of its 2023 comparative financial information due to an accounting policy change.
1
For audit coverage, 100% of consolidated revenue and 99% of consolidated assets were covered by independent external audit.
2
Kind to Animals
20
MagnetOs Putty, Granules, and Easypack Putty, which are primary products for the company's bone graft substitutes, are explicitly stated to be free of animal and human tissues.
1
The company's business model does not involve animal agriculture or the sourcing of eggs, meat, or dairy. Preclinical studies for the company's materials have involved animal testing, specifically in rabbits for a synthetic calcium phosphate material
2
and in an ovine model for MagnetOs.
3
However, no information is available regarding the volume of animals used in testing, the company's animal testing policy, or the extent to which non-animal testing methods are employed.
4
Data is also absent for cruelty-free certifications, humane certifications for operations, wildlife conservation impact, supplier audits for welfare compliance, R&D investment in animal-free technologies, and participation in animal-free R&D collaborations or public policy engagement.
5
No War, No Weapons
0
No sustainability data is available for Kuros Biosciences AG, making it impossible to assess any of the relevant metrics for the 'No War, No Weapons' ethical value.
1
Planet-Friendly Business
0
The provided articles do not contain specific, concrete data points or actions related to Kuros Biosciences AG's planet-friendly business practices. While a waste recycling target of 50% by 2024
1
and a carbon footprint reduction target of 25% by 2025
2
are mentioned, these are future targets and not evidence of current performance or achieved reductions. Both articles explicitly note a general lack of specific planet-friendly business metrics.
3
Respect for Cultures & Communities
0
No specific, concrete data points or facts were found in the provided articles that directly address any of the Key Performance Indicators for 'Respect for Cultures & Communities'. The articles primarily focus on financial performance, corporate governance, and general HR roles, or the broader private equity landscape in Switzerland, without detailing the company's engagement with local or indigenous communities, cultural impact assessments, or related policies and outcomes.
Safe & Smart Tech
0
No evidence available to assess KUROS BIOSCI.AG on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific quantitative data or concrete actions regarding waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education for Kuros Biosciences AG were found in the provided articles. The articles primarily discuss general industry trends, challenges, and potential solutions in pharmaceutical packaging sustainability without providing company-specific metrics or initiatives for Kuros.
1